Everolimus-induced mTOR inhibition has been shown to reduce human APP/Aβ and tau levels and improve cognitive function and the depression-like phenotype in the 3 × Tg-AD mouse model of AD (Cassano et al., 2019). This evidence concerns the gene MAPT and Alzheimer disease.